MARIMED INC.

MariMed Inc. reported a 6.1% increase in Q2 2026 revenue to $41.9 million, with year-to-date revenue reaching $81.4 million, up 5.2%. However, the company's net loss widened to $(3.6) million for the quarter and $(7.3) million for the six months ended June 30, 2026, primarily due to higher income tax provisions and interest expenses. Operating cash flow significantly improved to $3.2 million for the six-month period. The company also restructured its Series B convertible preferred stock and extended a note receivable.

MariMed Inc. reported record revenue of $41.9 million for the second quarter of 2026, a 6% increase year-over-year. Despite this growth, the company's GAAP net loss widened to $3.6 million from $1.4 million in the prior year quarter, and Non-GAAP Adjusted EBITDA decreased to $3.9 million from $4.8 million. Management highlighted strong sequential growth in both wholesale and retail businesses, with wholesale revenue up 6% and retail revenue up 7% sequentially, and expressed optimism about future growth strategies and potential federal cannabis reform.

MariMed Inc. reported a 4.2% increase in revenue to $39.5 million for the first quarter of 2026, while significantly narrowing its net loss to $3.8 million from $5.5 million in the prior year. The company achieved positive income from operations of $0.1 million, a notable improvement from a loss in the previous year, partly due to a substantial reduction in bad debt expense. However, net cash provided by operating activities decreased, and total liabilities increased during the quarter, alongside a restructuring of preferred stock into new preferred stock and notes payable.

MariMed Inc. reported its first-quarter 2026 financial results, showing a revenue increase to $39.5 million from $37.9 million year-over-year. The company significantly improved its GAAP net loss to $3.8 million from $5.5 million and saw a substantial rise in Non-GAAP Adjusted EBITDA to $3.6 million from $2.5 million. Management highlighted continued year-over-year growth, expanded distribution, and disciplined operational execution, alongside a strategic restructuring of Series B Convertible Preferred Stock to enhance liquidity and eliminate near-term refinancing risk.